- Home
- AGEN vs STHO Comparison
AGEN vs STHO Comparison
Compare AGEN & STHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | STHO |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 104.6M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGEN | STHO |
|---|---|---|
| Price | $3.05 | $8.29 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 613.6K | 53.7K |
| Earning Date | 03-10-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $106,829,000.00 | ★ $117,547,000.00 |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $68.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $6.06 |
| 52 Week High | $7.34 | $9.57 |
Technical Indicators
Market Signals| Indicator | AGEN | STHO |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 55.30 |
| Support Level | $2.76 | $7.76 |
| Resistance Level | $3.15 | $8.15 |
| Average True Range (ATR) | 0.18 | 0.29 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 61.00 | 96.86 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.